EP1399455A2 - Trizyklische dihydrochinolinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten - Google Patents

Trizyklische dihydrochinolinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten

Info

Publication number
EP1399455A2
EP1399455A2 EP02735551A EP02735551A EP1399455A2 EP 1399455 A2 EP1399455 A2 EP 1399455A2 EP 02735551 A EP02735551 A EP 02735551A EP 02735551 A EP02735551 A EP 02735551A EP 1399455 A2 EP1399455 A2 EP 1399455A2
Authority
EP
European Patent Office
Prior art keywords
branched
linear
group
formula
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02735551A
Other languages
English (en)
French (fr)
Inventor
Henri-Philippe Husson
Sylviane Giorgi-Renault
Stéphanie Desbene
John Hickman
Alain Pierre
Laurence Kraus-Berthier
Bruno Pfeiffer
Pierre Renard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of EP1399455A2 publication Critical patent/EP1399455A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Definitions

  • the present invention relates to new tricyclic derivatives of dihydro-quinolines, their process of preparation, the pharmaceutical compositions which contain them as well as their use as anticancer.
  • the compounds of the invention in addition to the fact that they are new, exhibit very advantageous antitumor properties.
  • R 9a , R 9b and R 9c identical or different, each represent a hydrogen atom or a linear or branched (C 1 -C 5 ) alkyl group,
  • X represents an oxygen or sulfur atom or a group chosen from CH 2 ,
  • R 9c represents a hydrogen atom or a linear or branched (Cj-C 6 ) alkyl group
  • Y represents an oxygen or sulfur atom
  • i represents a hydrogen atom or a group chosen from:
  • R 10a and R 10b identical or different, each represent a linear or branched (Ci-Ce) alkyl group, optionally substituted by a hydroxy or amino group (itself optionally substituted by one or two linear or branched (C 1 -C 5 ) alkyl groups, or else R 10 and Rio together with the nitrogen atom which carry them form a nitrogen heterocycle,
  • R 12 represents a hydrogen atom or an aryl or alkyl (Ci-C 6 ) linear or branched group optionally substituted by a group of formula NR 10a R 10b in which R 10a and Rio b , identical or different, each represents a linear or branched alkyl group (-C ⁇ ), optionally substituted by a hydroxy or amino group (itself optionally substituted by one or two alkyl groups (C ⁇ -C 6 ) linear or branched), or else R 10a and R 10b together with the nitrogen atom which carry them a nitrogen heterocycle,
  • R 2 , R 3 , i, R 5 , Re, R 7 and R 8 identical or different, each represent: - a hydrogen atom
  • alkyl group (C ⁇ -C 6 ) linear or branched optionally substituted by an amino group, which can itself be optionally substituted by one or two alkyl groups (Ci-C 6 ) linear or branched), an amino group optionally substituted by one or two alkyl groups (Ci-C 6 ) linear or branched, which can themselves be substituted by an amino group, alkylamino (C ⁇ - K 6 ) linear or branched or dialkylamino
  • (c T represents a mono- or bicyclic group of 5 to 12 members, aromatic or non-aromatic, optionally containing 1 or 2 heteroatoms chosen from O, S and N
  • R1 3 , R 1 and R 15 identical or different, each represent an atom of hydrogen or halogen or a group selected from alkyl (Ci-C 6) linear or branched (optionally substituted by an amino group, which may itself be optionally substituted by one or two groups alkyl
  • B j represents a linear or branched aryl, heteroaryl or arylalkyl (Ci-C 6 ) group
  • At least one of the groups R 2 to R 8 represents an aminoalkyl group (dC 6) linear or branched (optionally N-substituted by one or two alkyl (Ci-C 6) linear or branched), aT ⁇ linear or branched lammoalkylamino (Ci-C 6 ), linear or branched dialkylaminoalkylamino (Ci-C 6 ), linear or branched alkylaminoalkoxy (Ci-Ce), linear or branched dialkylaminoalkoxy (Ci-C 6 ) or -OPO (OH), or well R 2 with R 3 , or R 3 with R_ ⁇ , or Rt .
  • R 1 to R 15 represents a linear or branched aminoalkyl group (Ci-C 6 ) (optionally N- substituted by one or two linear or branched (C ⁇ -C 6 ) alkyl, linear or branched alkylaminoalkylamino (Ci-C 6 ), linear or branched dialkylaminoalkylamino (Ci-C 6 ), linear or branched alkylaminoalkoxy (C ⁇ -C 6 ) , dialkylaminoalkoxy (Ci-
  • hydrochloric hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, oxalic, methanesulphonic acids. , benzenesulfonic, camplioric.
  • aryl group is meant phenyl, biphenylyl, naphthyl, or tetrahydronaphthyl, each of these groups being optionally substituted by one or more atoms or groups, identical or different, chosen from halogen atoms and linear or branched (Cn-C 6 ) alkyl, hydroxy, linear or branched (Ci-C 6 ) alkoxy, linear or branched polyhaloalkyl (Ci-C ⁇ ), amino (optionally substituted by one or more alkyl groups (C ⁇ -C 6 ) linear or branched), nitro, acyl (C t -Ce) linear or branched or alkylenedioxy (Ci-C 2 ).
  • heteroaryl group is meant a 5 to 12-membered mono- or bicyclic aromatic group containing one, two or three heteroatoms chosen from oxygen, nitrogen or sulfur, it being understood that the heteroaryl may be optionally substituted by one or more atoms or groups, identical or different, chosen from halogen atoms and alkyl groups (-C ⁇ ) linear or branched, hydroxy, alkoxy (Ci-C 6) linear or branched polyhaloalkyl (C! -C 6) linear or branched, or amino (optionally substituted by one or more linear or branched (Ci-Ce) alkyl groups).
  • heteroaryl groups non-limiting mention may be made of thienyl, pyridyl, furyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, isoquinolyl and pyrimidinyl groups.
  • nitrogen heterocycle is meant a saturated monocyclic group of 5 to 7 members containing one, two or three heteroatoms, one of these heteroatoms being the nitrogen atom, and the additional heteroatom (s) possibly present being chosen from the atoms oxygen, nitrogen or sulfur.
  • the preferred nitrogen heterocycles are the pyrrolidinyl, piperidyl, morpholinyl or piperazinyl groups.
  • the preferred compounds of formula (I) are those for which ⁇ represents a double bond.
  • An advantageous aspect of the invention relates to the compounds of formula (I) for which R to R 8 , identical or different, each represent a group chosen from hydrogen, alkoxy (C ⁇ -C 6 ) linear or branched (optionally substituted by a group amino, alkylamino (C ⁇ -C 6 ) linear or branched or diakylamino (Ci-Ce) linear or branched) and OPO (OH) 2 .
  • Another advantageous aspect of the invention relates to the compounds of formula (I) for which R 2 and R 3; or R 3 and R 4 , form together with the carbon atoms which carry them a group of formula G.
  • An advantageous aspect of the invention relates to the compounds of formula (I) for which R 16 represents a hydrogen atom.
  • Another advantageous aspect of the invention relates to the compounds of formula (I) for which R 16 represents a linear or branched (C 1 -C 6 ) alkyl group.
  • An advantageous aspect of the invention relates to the compounds of formula (I) for
  • B J represents an aryl group.
  • Another advantageous aspect of the invention relates to the compounds of formula (I) for
  • R 1 represents a hydrogen atom or a linear or branched (C 1 -C 6 ) alkyl group.
  • the invention also extends to a process for preparing the compounds of formula (I) characterized in that a compound of formula (II) is reacted: in which R 1s R 2 , R 3 , R 4 and R 5 are as defined in formula (I),
  • R j , R 2 , R 3 , R, R 5 , R 6 , R 7 , R, R 16 and (B) are as defined
  • the compounds of the present invention in addition to the fact that they are new, exhibit advantageous pharmacological properties. They have cytotoxic properties which make them useful in the treatment of cancers.
  • the invention also extends to pharmaceutical compositions containing as active principle at least one compound of formula (I) with one or more inert, non-toxic and suitable excipients.
  • pharmaceutical compositions according to the invention mention may be made more particularly of those which are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous), nasal administration, simple or coated tablets, sublingual tablets, capsules, tablets, suppositories, creams, ointments, dermal gels, injections, oral suspensions, etc.
  • the useful dosage is adaptable according to the nature and severity of the condition, the route of administration as well as the age and weight of the patient and any associated treatments. This dosage varies from 0.5 mg to 2 g per 24 hours in one or more doses.
  • the starting materials used are known products or prepared according to known preparatory methods.
  • the expected product is obtained according to the process described in preparation A from 2-amino-6-methoxyphenol (the preparation of which is described in J. Org. Chem. 1926, 2007) and N, N-dimethyl-2- chloroethylamine.
  • the expected product is obtained according to the process described in Preparation A from 8-amino-2-naphthol and N, N-diethyl-3-chloropropylamine.
  • the expected product is obtained according to the process described in preparation D from 2-amino-6-methoxyphenol.
  • the expected product is obtained according to the process described in preparation A from 3-aminophenol and N, N-diethyl-2-chloroethylamine.
  • the expected product is obtained according to the process described in Preparation A from 3-hydroxybenzaldehyde and N, N-diethyl-2-chloroethylamine.
  • the expected product is obtained according to the process described in Example 1 from tetronic acid, 3,4,5-trimethoxybenzaldehyde and the compound described in preparation C.
  • the expected product is obtained according to the process described in Example 1 from tetronic acid, 3,4,5-trimethoxybenzaldehyde and 8-amino-2-naphthol. Melting point:> 260 ° C.
  • the expected product is obtained according to the process described in Preparation D from the compound of Example 4.
  • Stage B 8-oxo-7- (3,4,5-trimethoxyphenyl) -7,8,10,11 dihydrogenphosphate-tetrahydrobenzo [h] furo [3, 4-b] quinoline-2-yl
  • the expected product is obtained according to the process described in Example 1 from tetronic acid, 3,4,5-trimethoxybenzaldehyde and the compound described in preparation F. Melting point: 205 ° C.
  • the expected product is obtained according to the process described in Example 5 from tetronic acid, 3,4,5-trimethoxybenzaldehyde and the compound described in preparation E.
  • the expected product is obtained according to the process described in Example 1, replacing the compound of Preparation A with the compound of Preparation G. Melting point:> 205 ° C.
  • the expected product is obtained according to the process described in Example 1 from tetronic acid, 3-methoxy aniline and the compound described in preparation G. Melting point:> 205 ° C.
  • the expected product is obtained according to the process described in Example 1 from tetronic acid, the compound described in Preparation F and the compound described in preparation G.
  • Stage B 9- (3-Hydroxyphenyl) -4-methyl-6, 7-methylenedioxy-4, 9-dihydrofuro [3, 4-bjquinoline-1 (3H) -one
  • the expected product is obtained according to the process described in Example 1 from tetronic acid, 3-hydroxybenzaldehyde and the compound obtained in the preceding stage.
  • the expected product is obtained according to the process described in preparation D from the compound obtained in the previous stage.
  • Stage D 3- (4-methyl-6,7-methylenedioxy-1-oxo-1,3,4,9-tetrahydrofuro, 4-b] quinolin-9-yl) -phenyl dihydrogen phosphate
  • the expected product is obtained according to the process described in stage B of Example 5 starting from the compound obtained in the preceding stage.
  • Stage B Dibenzyl phosphate and 3- (9-methyl-6,7-methylenedioxy-l-oxo-1,3,4,9-tetrahydrofuro [3,4-b] quinoline-9-yl) -phenyl
  • the expected product is obtained according to the process described in preparation D from the compound obtained in the previous stage.
  • the cells are distributed in microplates and exposed to cytotoxic compounds.
  • the cells are then incubated for 2 days (L1210) or 4 days (A549, HT29).
  • the number of viable cells is then quantified by a colorimetric test, the Microculture Tetrazolium Assay (Cancer Res. 1987, 47, 939-942).
  • the compound of Example 4 has an IC 50 (concentration of cytotoxic agent which inhibits the proliferation of the treated cells by 50%) of 7 nM (L1210).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP02735551A 2001-05-23 2002-05-22 Trizyklische dihydrochinolinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten Withdrawn EP1399455A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0106791 2001-05-23
FR0106791A FR2825092B1 (fr) 2001-05-23 2001-05-23 Nouveau derives trycicliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2002/001716 WO2002094840A2 (fr) 2001-05-23 2002-05-22 Derives tricycliques de dihydroquinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
EP1399455A2 true EP1399455A2 (de) 2004-03-24

Family

ID=8863588

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02735551A Withdrawn EP1399455A2 (de) 2001-05-23 2002-05-22 Trizyklische dihydrochinolinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten

Country Status (18)

Country Link
US (1) US20040180917A1 (de)
EP (1) EP1399455A2 (de)
JP (1) JP2004529191A (de)
KR (1) KR20040008190A (de)
CN (1) CN1511161A (de)
AR (1) AR033914A1 (de)
BR (1) BR0209963A (de)
CA (1) CA2448197A1 (de)
CZ (1) CZ20033496A3 (de)
EA (1) EA200301172A1 (de)
FR (1) FR2825092B1 (de)
HU (1) HUP0401345A3 (de)
MX (1) MXPA03010597A (de)
NO (1) NO20035214L (de)
PL (1) PL364083A1 (de)
SK (1) SK16012003A3 (de)
WO (1) WO2002094840A2 (de)
ZA (1) ZA200308628B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013502619A1 (en) 2011-06-17 2014-02-17 Merck Sharp & Dohme Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
CA2936874A1 (en) 2014-01-15 2015-07-23 Guy Chabot Water soluble 4-azapodophyllotoxin analogs
US11731980B1 (en) 2023-03-22 2023-08-22 King Faisal University Furo[3,4-b]quinolone compounds as antibacterial agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2801310B1 (fr) * 1999-11-24 2004-04-16 Adir NOUVEAUX DERIVES DE DIHYDROFURO-[3,4-b]QUINOLEIN-1-ONES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02094840A2 *

Also Published As

Publication number Publication date
CN1511161A (zh) 2004-07-07
NO20035214D0 (no) 2003-11-24
KR20040008190A (ko) 2004-01-28
MXPA03010597A (es) 2004-03-09
EA200301172A1 (ru) 2004-04-29
HUP0401345A3 (en) 2006-11-28
WO2002094840A3 (fr) 2003-05-01
NO20035214L (no) 2003-11-24
FR2825092A1 (fr) 2002-11-29
CA2448197A1 (fr) 2002-11-28
HUP0401345A2 (hu) 2004-11-29
FR2825092B1 (fr) 2005-01-14
WO2002094840A2 (fr) 2002-11-28
SK16012003A3 (sk) 2004-06-08
CZ20033496A3 (cs) 2004-04-14
ZA200308628B (en) 2004-11-05
JP2004529191A (ja) 2004-09-24
BR0209963A (pt) 2004-04-13
PL364083A1 (en) 2004-12-13
US20040180917A1 (en) 2004-09-16
AR033914A1 (es) 2004-01-07

Similar Documents

Publication Publication Date Title
EP1103554B9 (de) Dihydrofuro-(3,4-b)-chinolein-1-on Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
FR2801054A1 (fr) Nouveaux derives de 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo [3,4-c]carbazole et 12,13-(pyranosyl)-furo[3,4-c]indolo [2,3-a]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1042326B1 (de) Acronycinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
WO2007017585A2 (fr) Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1664055B1 (de) 9-aminopodophyllotoxinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese derivate enthalten
CA2448191A1 (fr) Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1399455A2 (de) Trizyklische dihydrochinolinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten
EP1513833B1 (de) Neue 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinolin-4-one-derivate; verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
US9771325B2 (en) Tricyclic compounds and preparation thereof
FR2795071A1 (fr) Nouveaux derives de carboxylate de 7-oxo-2,3,7,14- tetrahydro-1h-benzo[b]pyrano[3,2,h] acridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0982308B1 (de) 8H-(2,3-b)-Pyrrolozin-8-one Derivate, Verfahren zur ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
EP1910376B1 (de) Neue camptothecin-analoga-verbindungen, herstellungsverfahren dafür und diese enthaltende pharmazeutische zusammensetzungen
EP1491544A1 (de) Benzo[a]pyrano[3,2-h]acridin-7-on Derivative, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
EP1561753A2 (de) Benzo[b]Chromennapthyridin-7-on- und Pyrano[2',3':7,8]quino[2,3-b]quinoxalin-7-on-Derivate, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Zusammensetzungen und ihre antitumoralen Eigenschaften zur Behandlung von Krebs
FR2879600A1 (fr) Nouveaux derives cinnamates de benzo[b]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2892417A1 (fr) Nouveaux composes aminoesterifies a cycle e hydrocarbone a sept chainons analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2902792A1 (fr) Nouveaux derives cinnamates de tetrahydro-7h-pyrano(2,3-c)acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2779725A1 (fr) Nouveaux derives de 5,10-dihydrodipyrido[2,3-b:2,3-e] pyrazine et 5,10-dihydrodipyrido[2,3-b:3,2-e]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2892418A1 (fr) Nouveaux composes aminoesterifies a cycle e hydrocarbone a six chainons analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2850655A1 (fr) Nouveaux derives d'oxazepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031107

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RENARD, PIERRE

Inventor name: PFEIFFER, BRUNO

Inventor name: KRAUS-BERTHIER, LAURENCE

Inventor name: PIERRE, ALAIN

Inventor name: HICKMAN, JOHN

Inventor name: DESBENE, STEPHANIE

Inventor name: GIORGI-RENAULT, SYLVIANE

Inventor name: HUSSON, HENRI-PHILIPPE

17Q First examination report despatched

Effective date: 20041222

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060527